Autolus Therapeutics plc
AUTL
Price:
$4.005
Market Cap:
$1.07B
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; a...[Read more]
Industry
Biotechnology
IPO Date
2018-06-22
Stock Exchange
NASDAQ
Ticker
AUTL
The ROE as of September 2024 (TTM) for Autolus Therapeutics plc (AUTL) is -66.76%
According to Autolus Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is -66.76%. This represents a change of 132.79% compared to the average of -28.68% of the last 4 quarters.
Autolus Therapeutics plc (AUTL) Historical ROE (quarterly & annually)
How has AUTL ROE performed in the past?
The mean historical ROE of Autolus Therapeutics plc over the last ten years is -56.04%. The current -66.76% ROE has changed 19.14% with respect to the historical average. Over the past ten years (40 quarters), AUTL's ROE was at its highest in in the December 2016 quarter at 0%. The ROE was at its lowest in in the December 2023 quarter at -69.23%.
Average
-56.04%
Median
-45.35%
Minimum
-186.93%
Maximum
-13.83%
Autolus Therapeutics plc (AUTL) ROE by Quarter and Year
Discovering the peaks and valleys of Autolus Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 275.12%
Maximum Annual ROE = -13.83%
Minimum Annual Increase = -66.17%
Minimum Annual ROE = -186.93%
| Year | ROE | Change |
|---|---|---|
| 2023 | -186.93% | 275.12% |
| 2022 | -49.83% | 9.88% |
| 2021 | -45.35% | -32.96% |
| 2020 | -67.65% | 39.21% |
| 2019 | -48.60% | 220.42% |
| 2018 | -15.17% | 9.64% |
| 2017 | -13.83% | -66.17% |
| 2016 | -40.90% | 13.46% |
Autolus Therapeutics plc (AUTL) Average ROE
How has AUTL ROE performed in the past?
The current ROE of Autolus Therapeutics plc (AUTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-94.04%
5-year avg
-79.67%
10-year avg
-56.04%
Autolus Therapeutics plc (AUTL) ROE vs. Peers
How is AUTL’s ROE compared to its peers?
Autolus Therapeutics plc’s ROE is greater than Cullinan Oncology, Inc. (-28.37%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Ikena Oncology, Inc. (-42.81%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Celcuity Inc. (-60.83%), greater than MediciNova, Inc. (-13.37%), greater than Rezolute, Inc. (-60.90%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Apellis Pharmaceuticals, Inc. (-139.02%),
| Company | ROE | Market cap |
|---|---|---|
| -28.37% | $1.04B | |
| -61.40% | $24.78M | |
| -122.70% | $1.25B | |
| -143.74% | $17.85M | |
| -24.63% | $133.38M | |
| 32.93% | $109.78M | |
| -68.93% | $312.42M | |
| -56.92% | $1.06B | |
| -39.58% | $549.60M | |
| -46.15% | $161.36M | |
| -42.81% | $81.56M | |
| -122.97% | $46.68M | |
| -60.83% | $557.67M | |
| -13.37% | $103.00M | |
| -60.90% | $240.80M | |
| -81.10% | $4.12B | |
| -139.02% | $5.00B |
Build a custom stock screener for Autolus Therapeutics plc (AUTL) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Autolus Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Autolus Therapeutics plc (AUTL) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Autolus Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Autolus Therapeutics plc's ROE?
How is the ROE calculated for Autolus Therapeutics plc (AUTL)?
What is the highest ROE for Autolus Therapeutics plc (AUTL)?
What is the 3-year average ROE for Autolus Therapeutics plc (AUTL)?
What is the 5-year average ROE for Autolus Therapeutics plc (AUTL)?
How does the current ROE for Autolus Therapeutics plc (AUTL) compare to its historical average?